scispace - formally typeset
Journal ArticleDOI

Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.

Reads0
Chats0
TLDR
Patients with advanced CKD taking apixaban had similar bleeding rates at 3 months compared with those taking warfarin, however, those who continued therapy had higher major bleeding rates with warFarin between 6 and 12 months.
Abstract
Background: Because of a lack of comparative data on anticoagulant use in the advanced chronic kidney disease (CKD) population, guidelines recommend warfarin for atrial fibrillation and venous thro...

read more

Citations
More filters
Journal ArticleDOI

Impact of direct oral anticoagulant off‐label doses on clinical outcomes of atrial fibrillation patients: A systematic review

TL;DR: A systematic review summarizes and evaluates DOACs use in real‐world practice and indicates discordance between guidelines and real-world practice regarding direct oral anticoagulant drug doses.
Journal ArticleDOI

Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants: A Systematic Review and Meta-analysis.

TL;DR: It is confirmed that there is no significant difference in risk of major GIB between patients receiving NOACs vs conventional treatment and meta-regression analysis failed to detect any potential confounding to impact the primacy outcome.
Journal ArticleDOI

Role of direct oral anticoagulants in patients with kidney disease

TL;DR: The currently available literature on DOAC use in kidney disease is summarized and knowledge gaps that represent important opportunities for prospective investigation are illustrated.
Journal ArticleDOI

Outcomes associated with apixaban vs warfarin in patients with renal dysfunction.

TL;DR: Apixaban may serve as a reasonable alternative compared with warfarin in patients with severe renal dysfunction and risk of thrombotic and bleeding events was lower in the apixaban group, and the severity of bleeding and thromBotic events was not different between groups.
References
More filters
Journal ArticleDOI

Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation

TL;DR: In patients with atrial fibrillation, rivaroxaban was noninferior to warfarin for the prevention of stroke or systemic embolism and there was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivroxaban group.
Related Papers (5)